SRZN
Surrozen, Inc. [SRZN] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
SRZN Stock Summary
Top SRZN Correlated Resources
SRZN
Top 10 Correlated ETFs
SRZN
Top 10 Correlated Stocks
SRZN
In the News
SRZN Financial details
Company Profile
- Volume Average 17.58K
- Market Capitalization 21.87M
- Employee 74
- CEO Mr. Craig C. Parker M.B.A.
- Headquarters South San Francisco,CA,US
- IPO Date 2021-01-11
-
Website
https://www.surrozen.com 
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
